RESUMEN
Autoimmune regulator (AIRE) gene mutation is responsible for the development of autoimmune-polyendocrinopathy-candidiasis ectodermal dystrophy, an organ-specific autoimmune disease with monogenic autosomal recessive inheritance. AIRE is predominantly expressed in medullary epithelial cells of the thymus and is considered to play important roles in the establishment of self-tolerance. AIRE contains two plant homeodomain (PHD) domains, and the novel role of PHD as an E3 ubiquitin (Ub) ligase has just emerged. Here we show that the first PHD (PHD1) of AIRE mediates E3 ligase activity. The significance of this finding was underscored by the fact that disease-causing missense mutations in the PHD1 (C311Y and P326Q) abolished its E3 ligase activity. These results add a novel enzymatic function for AIRE and suggest an indispensable role of the Ub proteasome pathway in the establishment of self-tolerance, in which AIRE is involved.
Asunto(s)
Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Ubiquitina-Proteína Ligasas/química , Ubiquitina-Proteína Ligasas/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , ADN Complementario/genética , Humanos , Técnicas In Vitro , Datos de Secuencia Molecular , Mutación Missense , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/genética , Estructura Terciaria de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Autotolerancia , Homología de Secuencia de Aminoácido , Factores de Transcripción/química , Ubiquitina-Proteína Ligasas/genética , Proteína AIRERESUMEN
Autoimmune polyendocrine syndrome type I (APS I) and idiopathic Addison's disease are both disorders with adrenal insufficiency but with differences in genetic background, clinical presentation, and extent of extraadrenal manifestations. In this study the major adrenal autoantigen identified with sera from patients with APS I was characterized by analyses using indirect immunofluorescence, Western blots of adrenal subcellular fractions and of recombinant proteins, immunoprecipitations of [35S]methionine-labeled lysates of a human steroid-producing cell line, and studies of enzymatic activity. Sera from patients with APS I, identifying cells in adrenal glands and testes involved in steroid synthesis, reacted in Western blots with a 53-kD antigen, which comigrated with the cytochrome P450 cholesterol side chain cleavage enzyme (SCC). The sera also immunoprecipitated this protein from lysates of radiolabeled adrenal cells. The enzymatic activity of SCC was inhibited by the APS I sera but not by control sera. Sera from patients with idiopathic Addison's disease did not react with the SCC. The results show that the autoimmune responses towards adrenal tissue in patients suffering from APS I and Addison's disease are remarkably selective and suggest that a determination of the antigen involved in a patient with autoimmune adrenal insufficiency will have diagnostic as well as prognostic implications.
Asunto(s)
Enfermedad de Addison/inmunología , Glándulas Suprarrenales/inmunología , Autoantígenos/sangre , Sistema Enzimático del Citocromo P-450/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Enfermedad de Addison/enzimología , Adolescente , Glándulas Suprarrenales/citología , Adulto , Animales , Western Blotting , Células Cultivadas , Niño , Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/inmunología , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Masculino , Poliendocrinopatías Autoinmunes/enzimología , Pruebas de Precipitina , Ratas , Esteroide 21-Hidroxilasa/inmunologíaRESUMEN
CONTEXT: Activation-induced cell death (AICD) is a major mechanism in the regulation of peripheral tolerance, and caspase-3 represents its major executioner. AICD impairment contributes to the persistence of autoreactive T cells, and defective AICD has been reported in autoimmune thyroiditis as well as in type 1 diabetes mellitus. OBJECTIVE: The objective of this study was to evaluate the involvement of caspase-3 in the regulation of AICD resistance in thyroid and polyendocrine autoimmunity. DESIGN/SETTINGS/PATIENTS/INTERVENTION: Caspase-3 expression was analyzed in peripheral blood lymphocytes from 26 adults (A-AT) and 25 children (Y-AT) affected by autoimmune thyroiditis and 13 individuals affected by chronic autoimmune thyroiditis plus Addison's disease [autoimmune polyendocrine syndrome-2 (APS-2)] in comparison with 32 age-matched normal control subjects (NC). OUTCOME MEASURES: Caspase-3 mRNA expression in peripheral T cells was evaluated by quantitative real-time PCR; protein expression of both procaspase-3 and activated caspase-3 by Western blot analysis was followed by scanning densitometry. RESULTS: Caspase-3 mRNA expression was significantly reduced in resting lymphocytes from both A-AT (P = 0.001) and Y-AT (P = 0.016) compared with NC. After lymphocyte activation, protein levels of caspase-3 active form were significantly reduced in A-AT (P = 0.023) and Y-AT (P = 0.001) compared with NC. The APS-2 group displayed characteristics similar to the A-AT group because both caspase-3 mRNA and protein active form levels were significantly reduced compared with NC (P = 0.004 and 0.002, respectively). CONCLUSION: Our data show that peripheral lymphocytes of subjects affected by thyroid autoimmunity or APS-2 show defective expression of the major executioner of AICD, thus potentially contributing to AICD resistance and to the development of autoimmunity.
Asunto(s)
Caspasa 3/metabolismo , Poliendocrinopatías Autoinmunes/enzimología , Linfocitos T/enzimología , Tiroiditis Autoinmune/enzimología , Adolescente , Adulto , Distribución por Edad , Estudios de Casos y Controles , Niño , Enfermedad Crónica , Femenino , Expresión Génica , Regulación Enzimológica de la Expresión Génica , Terapia de Reemplazo de Hormonas , Humanos , Activación de Linfocitos , Masculino , Persona de Mediana Edad , Poliendocrinopatías Autoinmunes/terapia , Tiroiditis Autoinmune/terapiaRESUMEN
Autoimmune polyendocrine syndrome type 1 (APS1), a monogenic disorder caused by AIRE gene mutations, features multiple autoimmune disease components. Infertility is common in both males and females with APS1. Although female infertility can be explained by autoimmune ovarian failure, the mechanisms underlying male infertility have remained poorly understood. We performed a proteome-wide autoantibody screen in APS1 patient sera to assess the autoimmune response against the male reproductive organs. By screening human protein arrays with male and female patient sera and by selecting for gender-imbalanced autoantibody signals, we identified transglutaminase 4 (TGM4) as a male-specific autoantigen. Notably, TGM4 is a prostatic secretory molecule with critical role in male reproduction. TGM4 autoantibodies were detected in most of the adult male APS1 patients but were absent in all the young males. Consecutive serum samples further revealed that TGM4 autoantibodies first presented during pubertal age and subsequent to prostate maturation. We assessed the animal model for APS1, the Aire-deficient mouse, and found spontaneous development of TGM4 autoantibodies specifically in males. Aire-deficient mice failed to present TGM4 in the thymus, consistent with a defect in central tolerance for TGM4. In the mouse, we further link TGM4 immunity with a destructive prostatitis and compromised secretion of TGM4. Collectively, our findings in APS1 patients and Aire-deficient mice reveal prostate autoimmunity as a major manifestation of APS1 with potential role in male subfertility.
Asunto(s)
Autoantígenos/metabolismo , Infertilidad Masculina/enzimología , Infertilidad Masculina/inmunología , Próstata/enzimología , Transglutaminasas/metabolismo , Animales , Autoanticuerpos/metabolismo , Células Epiteliales/enzimología , Femenino , Humanos , Masculino , Ratones Endogámicos C57BL , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Prostatitis/patología , Proteoma/metabolismo , Proteómica , Pubertad , Timo/metabolismo , Factores de Transcripción/deficiencia , Factores de Transcripción/metabolismo , Proteína AIRERESUMEN
Autoimmune polyendocrine syndrome type I (APS I) is characterized by autoantibodies, often directed towards tissue-specific enzymes in the affected organs. We have earlier reported the identification of tryptophan hydroxylase (TPH) and tyrosine hydroxylase (TH) as autoantigens in APS I associated with intestinal dysfunction and alopecia, respectively. These two enzymes, together with phenylalanine hydroxylase (PAH), constitute the group of biopterin-dependent hydroxylases, which all are involved in the biosynthesis of neurotransmitters. A clone encoding PAH was used for in vitro transcription/translation, followed by immunoprecipitation with sera from 94 APS I patients and 70 healthy controls. Of the APS I patients, 25% had PAH antibodies, and no reactivity was detected in the controls. No association with the main clinical components of APS I was found with PAH antibodies. Altogether, 59 sera from the 94 APS I patients reacted with at least one of TPH, TH, or PAH, whereas 35 showed no reactivity. Nineteen of the sera contained antibodies towards all enzymes, 12 to TPH only and 12 to TH only. No sera showed antibodies that reacted to only PAH. An immunocompetition assay demonstrated that the reactivity against PAH represents a cross-reactivity with TPH, whereas antibodies against TPH and TH are directed towards epitopes unique for the two enzymes.
Asunto(s)
Autoanticuerpos/sangre , Fenilalanina Hidroxilasa/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Autoantígenos/química , Autoantígenos/inmunología , Dominio Catalítico , Finlandia , Humanos , Italia , Modelos Moleculares , Noruega , Fenilalanina Hidroxilasa/química , Poliendocrinopatías Autoinmunes/enzimología , Conformación Proteica , Estructura Secundaria de Proteína , Valores de Referencia , Suecia , Triptófano Hidroxilasa/química , Triptófano Hidroxilasa/inmunología , Tirosina 3-Monooxigenasa/química , Tirosina 3-Monooxigenasa/inmunologíaRESUMEN
Patients with autoimmune polyendocrine syndrome type I (APS I) have autoantibodies against the enzyme aromatic L-amino acid decarboxylase (AADC) of pancreatic beta-cells. The aim of the present study was to investigate the presence of anti-AADC antibodies in a large cohort of patients with APS I, and in patients with isolated insulin-dependent diabetes mellitus (IDDM). We found autoantibodies against AADC in 35 of 69 patients (51%) with APS I but in none of 138 patients with isolated IDDM or 91 healthy controls. Among the patients with APS I, anti-AADC antibodies were more often found in those with hepatitis (11/12, 92%), than in those without hepatitis (24/57, 42%) (P = 0.003). Similarly, of 15 patients with vitiligo, 12 (80%) had anti-AADC antibodies, compared with 23/54 (43%) without vitiligo (P = 0.021). Of the 9 APS I patients with IDDM, 5 had antibodies against both AADC and glutamate decarboxylase, 2 against AADC only, and 2 against glutamate decarboxylase only. Interestingly, AADC is present in relatively large amounts in the liver, where its function is unknown. Thus, an autoimmune reactivity against AADC may be involved in the pathogenesis of autoimmune chronic active hepatitis and vitiligo in APS I patients, whereas the role of AADC in the development of IDDM in these patients remains to be determined.
Asunto(s)
Descarboxilasas de Aminoácido-L-Aromático/inmunología , Autoanticuerpos/sangre , Poliendocrinopatías Autoinmunes/inmunología , Adulto , Animales , Descarboxilasas de Aminoácido-L-Aromático/genética , Diabetes Mellitus Tipo 1/inmunología , Electroforesis en Gel de Poliacrilamida , Femenino , Finlandia , Humanos , Islotes Pancreáticos/enzimología , Masculino , Poliendocrinopatías Autoinmunes/enzimología , Biosíntesis de Proteínas , Ratas , Suecia , Transcripción GenéticaRESUMEN
Patients with idiopathic Addison's disease have autoantibodies reacting with adrenal cortex. If Addison's disease is associated with other endocrine immune diseases like autoimmune polyglandular diseases (APD) type I and type II, antibodies may recognize all steroid-producing cells. We showed previously that one antigen recognized by APD-I sera is the cytochrome P450c17 hydroxylase. We have now looked for antibodies to P450c17 and to two other key enzymes in the steroid biosynthetic pathway, the P450scc and P450c21, in a series of patients with isolated Addison's disease (8 patients) or with APD-I or APD-II (50 and 9 patients, respectively). The result of antienzyme antibodies were further correlated with the immunofluorescence pattern against adrenal gland, testis, ovary, and placenta, and with the clinical findings presented. In APD-I patients with Addison's disease and in APD-II patients, antibodies to at least one of the P450 enzymes were frequently found (positive findings in 81% and 78%, respectively). Such antibodies were less frequent in APD-I patients without Addison's disease (21%) and in the isolated Addison cases (25%). In APD-I, antibodies recognized as frequently P450c17 and P450scc, specific for all steroid-producing cells as the adrenal specific enzyme P450c21. In contrast, patients with APD-II or with the isolated Addison's disease reacted almost exclusively with P450c21. Immunofluorescence studies showed good correlation with the known fact that the zona glomerulosa of the adrenal cortex is devoid of the P450c17, that the Leydig cells of the testis and the theca interna cells of the ovary express P450c17 and P450scc, and that the placental trophoblasts express only P450scc. The presence of antibodies to P450scc or to at least one of the tested P450 enzymes correlated significantly to gonadal failure in the females but not in the males.
Asunto(s)
Enfermedad de Addison/enzimología , Aldehído-Liasas/inmunología , Autoanticuerpos/análisis , Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/inmunología , Sistema Enzimático del Citocromo P-450/inmunología , Poliendocrinopatías Autoinmunes/enzimología , Esteroide 21-Hidroxilasa/inmunología , Enfermedad de Addison/inmunología , Corteza Suprarrenal/química , Corteza Suprarrenal/enzimología , Adulto , Aldehído-Liasas/análisis , Autoanticuerpos/inmunología , Niño , Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/análisis , Sistema Enzimático del Citocromo P-450/análisis , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Immunoblotting , Masculino , Ovario/química , Ovario/enzimología , Placenta/química , Placenta/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Embarazo , Esteroide 17-alfa-Hidroxilasa , Esteroide 21-Hidroxilasa/análisis , Testículo/química , Testículo/enzimologíaRESUMEN
Autoimmune chronic active hepatitis (AI-CAH) is a feared component of autoimmune polyendocrine syndrome type I (APS I). In this study, immunoreactivity was assessed in sera from eight APS I patients, of whom three had AI-CAH, in an attempt to identify hepatic autoantigens. We performed indirect immunofluorescence staining of human and rat liver sections, Western blots on subcellular fractions of human and rat liver, immunoprecipitations of labelled aromatic L-amino acid decarboxylase (AADC) and cytochrome P450IA2 (CYP IA2) expressed by an in vitro transcription and translation system and studies of enzymatic activity. Autoantibodies against AADC were present in sera from all eight APS I patients, while immunoreactivity against CYP IA2 was only found in sera from the three APS I patients with AI-CAH. Enzymatic activity of CYP IA2 was inhibited by sera from APS I patients with AI-CAH but not by control sera. Our results show that CYP IA2 and AADC constitute hepatic autoantigens in patients with APS I and that immunoreactivity against CYP IA2 is associated with the presence of AI-CAH.
Asunto(s)
Descarboxilasas de Aminoácido-L-Aromático/inmunología , Autoantígenos/análisis , Citocromo P-450 CYP1A2/inmunología , Hígado/inmunología , Poliendocrinopatías Autoinmunes/enzimología , Animales , Descarboxilasas de Aminoácido-L-Aromático/genética , Autoanticuerpos/sangre , Autoantígenos/inmunología , Western Blotting , Citocromo P-450 CYP1A2/genética , Inhibidores del Citocromo P-450 CYP1A2 , Técnica del Anticuerpo Fluorescente Indirecta , Hepatitis Crónica/inmunología , Humanos , Hígado/química , Hígado/enzimología , Microsomas Hepáticos/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Pruebas de Precipitina , Biosíntesis de Proteínas , Ratas , Fracciones Subcelulares/química , Transcripción GenéticaRESUMEN
OBJECTIVE: To assess the prevalence of autoantibodies (Abs) to tryptophan hydroxylase (TPH) and aromatic l-amino acid decarboxylase (AADC) in patients with different autoimmune diseases and to analyse their respective epitopes. DESIGN: TPH and AADC Abs were measured in an immunoprecipitation assay using (35)S-labelled full-length and fragments of TPH and AADC. METHODS: Patients with different autoimmune adrenal diseases (n=84), non-adrenal autoimmune diseases (n=37), idiopathic vitiligo (n=8) and 56 healthy blood donors were studied. RESULTS: Fourteen of twenty-three (61%) of patients with autoimmune polyglandular syndrome (APS) type I and 1/34 (3%) of patients with isolated Addison's disease (AD) were positive for TPH Abs. None of the patients with APS type II (n=27), coeliac disease (n=10), autoimmune thyroid disease (AITD) (n=11), type 1 diabetes mellitus (DM) (n=16) or idiopathic vitiligo (n=8) was positive for TPH Abs. AADC Abs were detected in 12/23 (52%) patients with APS type I, in 1/29 (3%) patients with APS type II and 1/34 (3%) patients with isolated AD. None of the patients with coeliac disease, type 1 DM, AITD or idiopathic vitiligo was positive for AADC Abs. TPH Abs were found to interact with the C-terminal amino acids (aa) 308-423, central aa 164-205 and N-terminal aa 1-105 of the TPH molecule. AADC Ab binding epitopes were within the C-terminal aa 382-483, the central aa 243-381 and the N-terminal aa 1-167. CONCLUSIONS: Our study suggests that TPH Abs and AADC Abs react with several different epitopes and that different epitopes are recognized by different sera. The prevalence of TPH Abs and AADC Abs in patients with APS type I in our study is in agreement with previous reports. TPH Abs and AADC Abs were found very rarely in patients with other forms of autoimmune adrenal disease and were not detected in patients with non-adrenal autoimmune diseases.
Asunto(s)
Descarboxilasas de Aminoácido-L-Aromático/inmunología , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Triptófano Hidroxilasa/inmunología , Adolescente , Adulto , Anciano , Autoanticuerpos/sangre , Enfermedades Autoinmunes/enzimología , Niño , Preescolar , Epítopos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Pruebas de Precipitina , Esteroide 17-alfa-Hidroxilasa/sangre , Esteroide 21-Hidroxilasa/sangreRESUMEN
OBJECTIVE: Autoimmune polyglandular syndrome type 1 (APS-1) is a disease associated with defects of the autoimmune regulator gene and is characterized by autoimmune lesions of several tissues, predominantly endocrine glands, with multiple autoantibodies. In this study we describe autoantigenic epitopes on cholesterol side-chain cleavage enzyme (P450scc) using sera from Finnish and Sardinian patients with APS-1, and analyze the epitope reactivities during disease follow-up. METHODS: A series of P450scc cDNA fragments were expressed in E. coli and tested by immunoblotting assay using the patients' sera. RESULTS: Epitope regions were found over the whole P450scc molecule except the last N- (amino acids (aa) 1-40) and C-termini (aa 456-521). The strongest reactivity with patients' sera was found with central and C-terminal regions of the P450scc protein. All studied patients had IgG1 subclass antibodies. CONCLUSIONS: The results show that Finnish and Sardinian patients with APS-1 have similar, polyclonal immune reactions against P450scc, and that epitope reactivities did not change during the disease course. These results support the opinion that autoantibodies against P450scc and their epitope reactivity pattern are formed at an early stage of steroidogenic autoimmunity.
Asunto(s)
Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/inmunología , Colesterol/metabolismo , Mapeo Epitopo , Poliendocrinopatías Autoinmunes/inmunología , Adolescente , Adulto , Autoanticuerpos/análisis , Niño , Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/sangre , Femenino , Finlandia , Eliminación de Gen , Humanos , Immunoblotting , Inmunoglobulina G/química , Inmunoglobulina G/clasificación , Italia , Masculino , Poliendocrinopatías Autoinmunes/sangre , Poliendocrinopatías Autoinmunes/enzimologíaRESUMEN
By using an immunoprecipitation assay, we analysed reactivity of autoantibodies to human recombinant GAD65 and GAD67 in sera from patients with autoimmune polyendocrine syndrome Type II (APS II) with and without Type 1 (insulin-dependent) diabetes mellitus (IDDM) compared to patients with organ-specific autoimmunity. Overall antibodies to GAD65 were correlated with IDDM in all study groups, whereas GAD67 antibodies were associated with IDDM when APS II coexists. Antibodies to GAD65 and GAD67 were detected in 13 (44.8%) and 7 (24.1%) out of 29 APS II patients with IDDM, but in only 4 (13.8%) and 2 (6.9%) out of 29 APS II patients without IDDM, respectively (p < 0.05). In short-standing IDDM (< 1 year), antibodies to GAD67 were significantly more frequent in patients with APS II (5 of 9 [55.6%] subjects) compared to matched diabetic patients without coexisting polyendocrinopathy (1 of 18 [5.6%] subjects) (p < 0.02). The levels of GAD65 (142 +/- 90 AU) and GAD67 antibodies (178 +/- 95 AU) were significantly higher in patients with polyglandular disease than in patients with isolated IDDM (91 +/- 85 AU and 93 +/- 57 AU) (p < 0.02). Interestingly, all 11 GAD67 antibody positive subjects also had GAD65 antibodies (p < 0.0001), and in 10 of 11 anti-GAD67 positive sera the GAD67 antibodies could be blocked by either GAD67 or GAD65, suggesting the presence of cross-reactive autoantibodies. No correlation was observed between GAD antibodies and age, sex or any particular associated autoimmune disease, besides IDDM.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Diabetes Mellitus Tipo 1/inmunología , Glutamato Descarboxilasa/inmunología , Isoenzimas/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Adolescente , Adulto , Anciano , Especificidad de Anticuerpos , Autoanticuerpos/sangre , Niño , Diabetes Mellitus Tipo 1/enzimología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Peso Molecular , Especificidad de Órganos/inmunología , Poliendocrinopatías Autoinmunes/enzimologíaRESUMEN
Patients with autoimmune polyendocrine syndrome type 1 (APS-1) frequently have autoantibodies directed against the aromatic amino acid hydroxylases tryptophan hydroxylase (TPH) and tyrosine hydroxylase (TH). We aimed to characterize these autoantibodies with regard to their antigenic determinants, their influence on enzymatic activity and their clinical associations. In particular, we wanted to compare autoantibodies against the two different isoforms of TPH, which display different tissue distribution. Using sera from 48 Scandinavian APS-1 patients we identified 36 patients (75%) with antibodies against one or more of these three enzymes. Antibodies against TPH1, but not TPH2, were associated with malabsorption in the whole Scandinavian cohort, while TH antibodies were associated with dental enamel hypoplasia in Norwegian patients. Subsequent experiments with selected patient sera indicated that while the C-terminal domain was the immunodominant part of TPH1, the epitopes of TPH2 and TH were mainly located in the N-terminal regulatory domains. We also identified a TPH1 specific epitope involved in antibody mediated inhibition of enzyme activity, a finding that provides new insight into the enzymatic mechanisms of the aromatic amino acid hydroxylases and knowledge about structural determinants of enzyme autoantigens. In conclusion, TPH1, TPH2 and TH all have unique antigenic properties in spite of their structural similarity.
Asunto(s)
Autoanticuerpos/inmunología , Epítopos/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Triptófano Hidroxilasa/inmunología , Tirosina 3-Monooxigenasa/inmunología , Secuencia de Aminoácidos , Especificidad de Anticuerpos/inmunología , Autoanticuerpos/sangre , Sitios de Unión/genética , Sitios de Unión/inmunología , Biocatálisis , Estudios de Cohortes , Dinamarca , Epítopos/química , Epítopos/metabolismo , Finlandia , Humanos , Immunoblotting , Isoenzimas/genética , Isoenzimas/inmunología , Isoenzimas/metabolismo , Modelos Moleculares , Datos de Secuencia Molecular , Noruega , Poliendocrinopatías Autoinmunes/sangre , Poliendocrinopatías Autoinmunes/enzimología , Estructura Terciaria de Proteína , Suecia , Triptófano Hidroxilasa/genética , Triptófano Hidroxilasa/metabolismo , Tirosina 3-Monooxigenasa/genética , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
Autoimmune polyendocrine syndrome type I (APS I) is a rare hereditary condition considered a model disease for organ specific autoimmunity. A wide range of autoantibodies targeting antigens present in the affected organs have been identified. Autoantibodies against aromatic L-amino acid decarboxylase (AADC) are present in about 50% of APS I patients. In order to increase our understanding of autoantibody specificity in APS I, the aim of the present study was to localize target regions on AADC recognized by sera from APS I patients. Using several complementing strategies, we have shown that autoantibodies against AADC mainly recognize conformational epitopes. The major antigenic determinants were detected N-terminally to amino acid residue 237. Replacement of amino acids 227-230 (ERDK) with alanine residues reduced the reactivity towards AADC by >80% in all patient sera tested, suggesting that amino acids 227-230 are an important part of an immunodominant epitope.
Asunto(s)
Descarboxilasas de Aminoácido-L-Aromático/inmunología , Mapeo Epitopo/métodos , Descarboxilasas de Aminoácido-L-Aromático/genética , Autoanticuerpos , Carboxiliasas/genética , Carboxiliasas/inmunología , Humanos , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
Patients with the autosomal recessively inherited autoimmune polyendocrine syndrome type I (APS I) have autoantibodies directed against several endocrine and nonendocrine organs. In this study a new autoantigen related to this syndrome, tyrosine hydroxylase, was identified in sera from patients with alopecia areata through immunoscreening of a scalp cDNA library. Immunoreactivity against in vitro expressed tyrosine hydroxylase was found in 41 (44%) of the 94 APS I patients studied and this reactivity correlated with the presence of alopecia areata (P = 0.02). These findings further stress the importance of enzymes involved in neurotransmitter biosynthesis as important immune targets in APS I.
Asunto(s)
Autoanticuerpos/sangre , Autoantígenos/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Tirosina 3-Monooxigenasa/inmunología , Alopecia Areata/enzimología , Alopecia Areata/inmunología , Autoantígenos/genética , Europa (Continente) , Biblioteca de Genes , Humanos , Isoenzimas/genética , Isoenzimas/inmunología , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/genética , Cuero Cabelludo/enzimología , Síndrome , Tirosina 3-Monooxigenasa/genéticaRESUMEN
A full-length rat cDNA clone encoding aromatic L-amino acid decarboxylase (AADC) (E.C. 4.1.1.28) was used for in vitro transcription and translation. The enzyme had catalytic activity (0. 2 pmol serotonin/microl lysate per min), and was stimulated 2.5-fold by the addition of excess pyridoxal phosphate. On size exclusion chromatography, AADC eluted as a single activity peak with an apparent mol. wt of 93 kD. This activity peak was immunoprecipitated by sera from patients with autoimmune polyendocrine syndrome type I (APS I) containing autoantibodies against AADC. Serum and purified IgG from these patients inhibited the enzyme activity (non-competitively) by 10-80%, while sera from APS I patients without autoantibodies and controls did not. This finding confirms and extends previous observations that APS I patients have inhibitory antibodies against key enzymes involved in neurotransmitter biosynthesis.
Asunto(s)
Inhibidores de Descarboxilasas de Aminoácidos Aromáticos , Autoanticuerpos/metabolismo , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Adolescente , Adulto , Animales , Descarboxilasas de Aminoácido-L-Aromático/genética , Catálisis , Cromatografía en Gel , Femenino , Humanos , Sueros Inmunes , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Biosíntesis de Proteínas , Fosfato de Piridoxal/farmacología , Ratas , Transcripción GenéticaRESUMEN
Tryptophan hydroxylase antibodies, associated with gastrointestinal disease in autoimmune polyendocrine syndrome type 1, are specific for this disease and not present in patients with other bowel disorders or healthy controls.
Asunto(s)
Autoanticuerpos/sangre , Enfermedades Intestinales/etiología , Poliendocrinopatías Autoinmunes/enzimología , Poliendocrinopatías Autoinmunes/inmunología , Triptófano Hidroxilasa/inmunología , Humanos , Enfermedades Intestinales/sangre , Enfermedades Intestinales/enzimología , Enfermedades Intestinales/inmunología , Poliendocrinopatías Autoinmunes/sangre , Poliendocrinopatías Autoinmunes/complicaciones , Triptófano Hidroxilasa/sangreRESUMEN
Antibodies to glutamic acid decarboxilase (GAD-Abs) are present in the serum of 60-80% of newly diagnosed type 1 diabetes (DM1) patients and patients with autoimmune polyendocrine syndrome (APS) associated with DM1. Higher titre of GAD-Abs are also present in the serum of 60% of patients with stiff-man syndrome (SMS) and all reported patients with cerebellar ataxia associated with polyendocrine autoimmunity (CAPA). Several studies suggest that GAD-Abs may play a critical role in the pathogenesis of SMS and CAPA but little is known about T-cell responsiveness to GAD-65 in these neurological diseases. To analyse cell-mediated responses to GAD, we studied the peripheral blood lymphocyte proliferation and cytokine responses to recombinant human GAD-65 in 5 patients with SMS, 6 with CAPA, 9 with DM1, 8 with APS and 15 control subjects. GAD-65-specific cellular proliferation was significantly higher in SMS than in CAPA, DM1, APS or controls. In contrast, only T cells from CAPA patients showed a significantly high production of interferon-gamma after GAD stimulation, compared to all other patients and controls. No differences were found for IL-4 production. These results suggest that, despite similar humoral autoreactivity, cellular responses to GAD are different between SMS and CAPA, with a greater inflammatory response in CAPA, and this difference may be relevant to the pathogenesis of these diseases.
Asunto(s)
Ataxia Cerebelosa/inmunología , Glutamato Descarboxilasa/inmunología , Poliendocrinopatías Autoinmunes/inmunología , Síndrome de la Persona Rígida/inmunología , Linfocitos T/inmunología , Adolescente , Adulto , Anciano , Autoanticuerpos/sangre , Células Cultivadas , Ataxia Cerebelosa/diagnóstico , Ataxia Cerebelosa/enzimología , Niño , Citocinas/biosíntesis , Diabetes Mellitus Tipo 1/inmunología , Femenino , Prueba de Histocompatibilidad , Humanos , Activación de Linfocitos , Masculino , Persona de Mediana Edad , Poliendocrinopatías Autoinmunes/diagnóstico , Poliendocrinopatías Autoinmunes/enzimología , Síndrome de la Persona Rígida/diagnóstico , Síndrome de la Persona Rígida/enzimologíaRESUMEN
PURPOSE OF REVIEW: The goal of this review is to provide an overview of rapidly evolving information on a new group of genetic inborn errors affecting ubiquitination and proteasomal degradation of proteins and to suggest a classification scheme for these disorders. The relevant genes encode ubiquitin, ubiquitin enzymes (E1 and many E2s and E3s), deubiquitinating enzymes, proteasomal subunits, and substrates undergoing ubiquitination. RECENT FINDINGS: Since the initial recognition that Angelman syndrome is caused by maternal deficiency of the E6-AP ubiquitin E3 ligase (gene symbol UBE3A), several. other disorders of E3 ligases have been identified, including autosomal recessive juvenile Parkinson disease, the APECED form of autoimmune polyendocrinopathy syndrome, von Hippel-Lindau syndrome, and congenital polycythemia. Disorders that disturb ubiquitin regulatory signaling include at least two subtypes of Fanconi anemia, the BRCA1 and BRCA2 forms of breast and ovarian cancer susceptibility, incontinentia pigmenti, and cylindromatosis. Many disorders affect ubiquitin pathways secondarily. SUMMARY: The authors propose both a genetic and a functional classification for disorders of ubiquitination and proteasomal degradation, as follows. Genetic classes include mutations in (1) the UBB ubiquitin gene; (2) enzymes of ubiquitination including E1, E2, E3, and related proteins; (3) deubiquitinases; (4) proteasomal subunits; and (5) substrates of ubiquitination. Functional classes include defects in (1) proteolytic degradation, (2) ubiquitin signaling, and (3) subcellular localization of substrates. Additional functional classes are likely to be defined, and individual disorders may involve multiple functional defects.